University of Washington

Phaserx, Inc.

University of Rochester

Genevant Sciences Gmbh

Danielle Benoit

Allan Sachs Hoffman

Patrick S Stayton

Anna S Gall

Craig L Duvall

Paul Hickok Johnson

Anthony Convertine

Mary Gallagher Prieve

Robert W Overell

Charbel Diab

Priyadarsi De

Amber E E Paschal

Anthony J Convertine

Paul Johnson

J Edward Puzas

Maureen Newman

Tzong-Jen Sheu

Amber E Paschal

Hyun Koo

Megan L Falsetta Wood

Michael Hoffman

Robert Overell

Benjamin Frisch

Marlise I Klein

Amber Ee Paschal

Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.

Micellic assemblies

The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3&#x3b2;. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation or treatment.

Compositions and methods for controlled localized delivery of bone forming therapeutic agents

The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3&#x3b2;. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation.

Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.

Diblock copolymers and polynucleotide complexes thereof for delivery into cells

Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.

The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.

Nanoparticles for controlled release of anti-biofilm agents and methods of use

Provided is a method for increasing proliferation of mesenchymal stem cells. The method entails contacting the cells with 6-bromoindirubin-3'-oxime (BIO). This results in robust proliferation and 'stemness' in a dose-dependent fashion, as indicated by the gene expression of two stem cell genes: Sox2 and Nanog.

Methods and compositions for mesenchymal stem cell proliferation

Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.

Polymeric carrier

Growing community of inventors

Rochester, NY, United States of America

Danielle Benoit